Wide Ranks

MREO

Mereo BioPharma Group plc

3.56

Top Statistics
Market Cap 552 M Forward PE -121.71 Revenue Growth 0.00 %
Current Ratio 6.10 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -71.72 Enterprise / Revenue 2687.75 Price To Sales Trailing12 Months 552.32
Profitability
Profit Margins 0.00 % Operating Margins -3806.60 %
Balance Sheet
Total Cash 80 M Total Cash Per Share 0.1040 Total Debt 6 M
Total Debt To Equity 9.21 Current Ratio 6.10 Book Value Per Share 0.4690
All Measures
Short Ratio 849.00 % Message Board Id finmb_307970474 Shares Short Prior Month 5 M
Return On Equity -0.7364 City London Uuid 2bb59234-2dd4-3418-a5f3-ada28f11788c
Previous Close 3.40 First Trade Date Epoch Utc 1 B Book Value 0.4690
Total Debt 6 M Volume 408000 Price To Book 7.59
Fifty Two Week Low 1.91 Total Cash Per Share 0.1040 Total Revenue 1000000
Shares Short Previous Month Date 1 B Target Median Price 5.49 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -3806.60 % Target Mean Price 5.64
Net Income To Common -45316000 Short Percent Of Float 0.0430 Implied Shares Outstanding 140 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 80 M Next Fiscal Year End 1 B
Revenue Per Share 0.0070 Held Percent Insiders 0.0102 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 3.40
Target Low Price 4.72 Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.11
Open 3.44 Free Cashflow -20088750 Dividend Yield 0.00 %
Return On Assets -0.3065 Time Zone Short Name EST Trailing Eps -0.3000
Day Low 3.39 Address1 One Cavendish Place Shares Outstanding 155 M
Price Hint 4 Target High Price 6.28 Website https://www.mereobiopharma.com
52 Week Change 0.7033 Average Volume 751440 Forward Eps -0.0300
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 583.40 %
Is_sp_500 False Regular Market Day High 3.59 Profit Margins 0.00 %
Debt To Equity 9.21 Fifty Two Week High 5.02 Day High 3.59
Shares Short 5 M Regular Market Open 3.44 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 2687.75 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0363 Operating Cashflow -30203000 Currency USD
Time Zone Full Name America/New_York Market Cap 552 M Is_nasdaq_100 False
Zip W1G 0QF Quote Type EQUITY Industry Biotechnology
Long Name Mereo BioPharma Group plc Regular Market Day Low 3.39 Held Percent Institutions 0.6829
Current Price 3.56 Address2 4th Floor Enterprise To Ebitda -71.72
Financial Currency USD Current Ratio 6.10 Gross Margins 127.30 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United Kingdom
Float Shares 489 M Two Hundred Day Average 3.74 Enterprise Value 2 B
Price To Sales Trailing12 Months 552.32 Forward PE -121.71 Regular Market Volume 408000
Ebitda -37476000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.

The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.

In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.

The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.

Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.